Our History

MorphoSys founded in Martinsried, Germany by Dr. Simon Moroney and Prof. Dr. Andreas Plückthun

Invention of the HuCAL Concept, synthetic library consisting of human antibody sequences for the generation of highly specific, fully human antibodies. Inventor: Achim Knappik, Dr. Simon Moroney, Prof. Dr. Andreas Plückthun (and others)

Move to IZB Gründerzentrum with ~30 employees; first partnership with Pharmacia & Upjohn

MorphoSys is listed on the Frankfurt stock exchange; partnership with Bayer

Move to our own building in Martinsried, ~100 employees

Growth through partnerships: Novartis, Janssen, Schering-Plough, Pfizer, Merck

Own drug development, e.g. with Xencor, GSK and others

Move to new building in Planegg: state-of-the-art office and lab, unifying all teams under one roof

Tremfya^® is the first drug based on MorphoSys’ antibody technology to receive regulatory approval. Developed and marketed by Janssen for the treatment of plaque psoriasis

MorphoSys is listed on NASDAQ; MorphoSys US Inc. is established; MorphoSys and I-Mab enter strategic development and commercialization agreement for MOR210/TJ210

Jean-Paul Kress appointed as MorphoSys CEO in September

MorphoSys and Incyte enter into collaboration and licensing agreement to further develop and commercialize tafasitamab globally

The U.S. Food and Drug Administration (FDA) grants accelerated approval for Monjuvi® (tafasitamab-cxix) in combination with lenalidomide in patients with a certain type of lymphoma

MorphoSys and Cherry Biolabs entered into a licensing agreement for innovative, multispecific Hemibody technology; MorphoSys and Xencor enter into collaboration exploring further combinations with tafasitamab and Xencor’s CD20xCD3 bispecific plamotamab

Acquisition of Constellation Pharmaceuticals, a U.S. biotech company that adds exciting, pioneering science and two new product candidates to our pipeline

Conditional approvals for Minjuvi^® (tafasitamab) in the European Union and Canada in combination with lenalidomide in patients with a certain type of lymphoma

Comprehensive Phase 3 MANIFEST-2 results of pelabresib and ruxolitinib combination in first-line myelofibrosis presented at the American Society of Hematology (ASH) 2023 Annual Meeting and Exposition

MorphoSys enters into Business Combination Agreement to be acquired by Novartis for € 2.7 billion equity value and into Purchase Agreement with Incyte for the sale of tafasitamab